NICE rejects Novartis's Xolair for paediatric asthma
This article was originally published in Scrip
Executive Summary
The National Institute for health and Clinical Excellence (NICE), the heath technology appraisal body for England and Wales, is still poised to decline Novartis's Xolair for treating severe persistent allergic asthma in children aged between six and 11 years on the NHS.